Comparing Outcomes of Coronary Artery Bypass Grafting Among Large Teaching and Urban Hospitals in China and the United States

Zhe Zheng, MD, PhD*; Heng Zhang, MD, PhD*; Xin Yuan, MD, PhD*; Chenfei Rao, MD, PhD; Yan Zhao, MD; Yun Wang, PhD; Sharon-Lise Normand, PhD; Harlan M. Krumholz, MD, SM; Shengshou Hu, MD, PhD

Background—Coronary artery disease is prevalent in China, with concomitant increases in the volume of coronary artery bypass grafting (CABG). The present study aims to compare CABG-related outcomes between China and the United States among large teaching and urban hospitals.

Methods and Results—Observational analysis of patients aged ≥18 years, discharged from acute-care, large teaching and urban hospitals in China and the United States after hospitalization for an isolated CABG surgery. Data were obtained from the Chinese Cardiac Surgery Registry in China and the National Inpatient Sample in the United States. Analysis was stratified by 2 periods: 2007, 2008, and 2010; and 2011 to 2013 periods. The primary outcome was in-hospital mortality, and the secondary outcome was length of stay. The sample included 51,408 patients: 32,040 from 77 hospitals in the China-CABG group and 19,368 from 303 hospitals in the US-CABG group. In the 2007 to 2008, 2010 period and for all-age and aged ≥65 years, the China-CABG group had higher mortality than the US-CABG group (1.91% versus 1.58%, P=0.059; and 3.12% versus 2.20%, P=0.004) and significantly higher age-, sex-, and comorbidity-adjusted odds of death (odds ratio, 1.58; 95% confidential interval, 1.22–2.04; and odds ratio, 1.73; 95% confidential interval, 1.24–2.40). There were no significant mortality differences in the 2011 to 2013 period. For preoperative, postoperative, and total hospital stay, respectively, the median (interquartile range) length of stay across the entire study period between China-CABG and US-CABG groups were 9 (3) versus 6 (3), and 20 (7) versus 14 (7) days (all P<0.001). This difference did not change significantly over time.

Conclusions—In 2011 to 2013, there was no significant difference in in-hospital mortality among patients who underwent an isolated CABG surgery in large teaching and urban hospitals in China and the United States. The longer length of stay in China may represent an opportunity for improvement. (Circ Cardiovasc Qual Outcomes. 2017;10:e003327. DOI: 10.1161/CIRCOUTCOMES.116.003327.)

Key Words: comorbidity • coronary artery bypass grafting • coronary artery disease • hospital mortality • length of stay

Cardiovascular disease is a leading cause of death worldwide, and coronary artery bypass grafting (CABG) is among the most common major medical procedures for treating coronary artery diseases (CAD). Several innovations, such as minimally invasive CABG surgery, off-pump CABG surgery, and antiplatelet therapy have been adopted widely, with the promise of improved clinical outcomes compared with older CABG techniques. Because the United States...
WHAT IS KNOWN

• The United States healthcare delivery system’s recent focus on quality improvement efforts and cost containment has increased attention on reducing procedure complications and the overall length of stay associated with CABG.

• There have been extensive, nationwide efforts to monitor and improve the quality of cardiac surgery care in China.

WHAT THE STUDY ADDS

• In 2011 to 2013, there was no significant difference in in-hospital mortality among patients who underwent an isolated CABG surgery in China and the United States.

• There is room for improvement in CABG-specific length of hospital stay in Chinese hospitals.

• Improvement is needed to reduce the difference in CABG care between large teaching hospitals and small, often nonteaching hospitals.

• Improving CABG care in China can provide insight about the cardiac surgical outcomes between these 2 countries, and it is unclear how the performance of centers in China benchmarks against those in the United States. Databases including the Chinese Cardiac Surgery Registry (CCSR) are nationwide registries in mainland China. Until now, it has become the largest and most representative database in cardiovascular surgery all over the world.

• In China, CABG utilization rates were observed in the United States. Until now, there have been no existing studies comparing cardiac surgical outcomes between these 2 countries, and it is unclear how the performance of centers in China benchmarks against those in the United States. Databases including the Chinese Cardiac Surgery Registry (CCSR) are nationwide registries in mainland China. Until now, it has become the largest and most representative database in cardiovascular surgery all over the world.

Methods

Study Sample

In 2004, CCSR was started as the first multicenter cardiac surgery registry in mainland China. Until now, it has become the largest and most representative database in cardiovascular surgery all over the country. The registry includes all patients who underwent CABG or valve surgery at each participating hospital. Participating hospitals received detailed information on data collection requirements and definitions of variables. Training on data collection was provided to each hospital and was performed by trained clinical nurses or residents. A standardized case report form, containing demographic, preoperative risk factors, operative information, postoperative treatment course, and surgical outcomes, was required to be completed for each hospitalization by participating hospitals. This form was then submitted to the data processing center of the CCSR and entered into the database by 2 data specialists. Two reviewers from the data processing center abstracted a random sample of 5% to 10% of medical records per hospital through on-site auditing at 6-month intervals. The electronic values submitted by the hospitals were compared with the values in the medical records. When a disagreement occurred, a supervisor adjudicated the variable to determine the final value. The China-CABG data were drawn from the CCSR, which includes 102 hospitals for patients undergoing CABG from January 1, 2004, to December 31, 2013, with the exception of 2006 and 2009 in which no data were collected. Most of the participating hospitals are large teaching hospitals located in urban areas (annual cardiac surgical volumes >100).

The US-CABG data were drawn from the 2007 to 2013 NIS data developed as a part of the Healthcare Cost and Utilization Project and sponsored by the Agency for Healthcare Research and Quality. The NIS is the largest all-payer inpatient care database in the United States. Before 2012, the sampling method was to sample 20% of hospitals and then retain all discharges from each sampled hospital. This national sample represents 20% of annual hospitalizations or ≥8 million hospitalizations. In 2012, Agency for Healthcare Research and Quality changed the sampling method for NIS. The new method samples 20% of all discharges from all hospitals. To align the 2007 to 2011 NIS data with 2012 and 2013 NIS data, we first randomly selected 20% discharges from each of the 2007 to 2011 NIS data sets and then randomly selected 20% of hospitals from the 2012 and 2013 NIS data sets and appended these 2 subsamples together.

For this study, we restricted data to patients aged ≥18 years who underwent an isolated CABG, including on-pump or off-pump procedures during the index hospitalization. To facilitate data presentation and analysis, we combined data from 2 measurement periods: 2007–2008, 2009–2011, and 2012 to 2013. We appended the China-CABG data and US-CABG data as one data set and excluded hospitals that had CABG volume <25 in any of these 2 periods.

Outcomes

Our primary outcomes included in-hospital mortality, defined as all-cause death during an index CABG hospitalization; total LOS, defined as the difference in dates between discharge and admission; preoperative LOS, defined as the difference in dates between operation and admission; and postoperative LOS, defined as the difference in dates between discharge and operation. If the date of operation was the same as the date of admission, preoperative LOS was counted as 0; if the date of discharge was the same as the date of operation, postoperative LOS was counted as 0. Our second outcome was postoperative 5-day mortality, defined as all-cause death during an index CABG hospitalization within 5 days of the operative date. Because

Patient Characteristics

Patient characteristics included age, sex, prior CABG or valve surgery, obesity, and prior or current cigarette smoking, and common comorbidities were abstracted from medical records in the China-CABG data, but were identified based on the International Classification of Diseases 9th Revision Clinical Modification principal discharge procedure codes 36.10 to 36.17 and 36.19, excluding patients with nonisolated CABG procedure codes (Table I in the Data Supplement) during the index hospitalization. To facilitate data presentation and analysis, we combined data from 2 measurement periods: 2007–2008, 2009–2011, and 2012 to 2013. We appended the China-CABG data and US-CABG data as one data set and excluded hospitals that had CABG volume <25 in any of these 2 periods.

Outcomes

Our primary outcomes included in-hospital mortality, defined as all-cause death during an index CABG hospitalization; total LOS, defined as the difference in dates between discharge and admission; preoperative LOS, defined as the difference in dates between operation and admission; and postoperative LOS, defined as the difference in dates between discharge and operation. If the date of operation was the same as the date of admission, preoperative LOS was counted as 0; if the date of discharge was the same as the date of operation, postoperative LOS was counted as 0. Our second outcome was postoperative 5-day mortality, defined as all-cause death during an index CABG hospitalization within 5 days of the operative date. Because
patients in the China-CABG group had longer LOS than those in the US-CABG group, this outcome allows us to assess in-hospital mortality between 2 groups with equal LOS.

**Statistical Analysis**

We combined 2007, 2008, and 2010 as one period and 2011 to 2013 together as another period to compare the outcomes by 2 periods. Mortality was expressed as a percentage and preoperative LOS and postoperative LOS as median (interquartile range) days. All outcomes were compared between the China-CABG and the US-CABG groups. We used the Cochran–Armitage test to determine the statistical significance of the comparisons. We fitted 3 mixed models with a logit link function to assess the difference in in-hospital mortality between the 2 patients groups for each study period separately. Model 1 only included mortality as an outcome without adjusting for patient characteristics, model 2 adjusted for patient age and sex, and model 3 adjusted for patient age, sex, and comorbidities. Each model included a China–US indicator (1 for China and 0 for United States) and reported the odds ratio of this indicator. An odds ratio of >1.0 would represent that compared with the US-CABG group, the China-CABG group had higher in-hospital mortality. To assess differences in mortality between China and the United States by age group, we repeated all models for 2 age categories (18–64 years and ≥65 years) to be able to potentially compare with the US Medicare population. To assess the trends in mortality over time between China and the United States, we fitted a mixed model with an ordinal time variable, corresponding to years 2007 (time=0) to 2013 (time=5), the China–US indicator, and an interaction term of the time and China-US indicator, adjusting for patient age, sex, and comorbidities. We also fitted a mixed model with the time variable, the China–US indicator, and the time and China–US interaction to compare the difference in LOS between the China-CABG and US-CABG groups over time, adjusting for patient characteristics. Because LOS was skewed, we applied a log transformation to normalize its distribution. The estimated coefficient of the China–US indicator represents the percentage change in LOS between China and United States. Because patients were clustered within hospitals, all models were fitted with hospital random intercepts to account for within-hospital and between-hospital variations.

To account for the potential imbalances in patient characteristics between the 2 groups, we conducted a second analysis using stabilized inverse probability weighting. Specifically, we weight each patient by the patient’s inverse propensity score of being in the US-CABG group. To obtain the propensity score, we fitted a logistic model with the US-CABG group as an outcome and all patient characteristics included in the above primary mixed models as covariates. To account for potential sampling variation between 2007 to 2011 (except 2009) and 2012 to 2013, because of changes in sampling approach in the NIS data described previously, we conducted a simulation analysis with a nonparametric bootstrap method. Specifically, for the China-CABG data, we randomly selected discharges for each year, with a sample size equal to that year’s total discharges but with replacements; for the 2007 to 2011 (except 2009) US-CABG data, we randomly selected 20% of discharges with replacements; for the 2012 to 2013 US-CABG data, we first randomly selected 20% of hospitals with replacements and then obtained all CABG discharges for these hospitals. All selections were stratified by year. We then appended the 3 resampled data sets together and fitted the models to estimate the odds ratio of death for the China-CABG group, referring to the US-CABG group, for each study period and age group. We repeated this process 10000 times to obtain the distributions of the odds ratios and their 95% confidence intervals. All statistical tests were performed using a 2-sided α value of 0.05. Analyses were conducted using SAS, Version 9.3 64-bit (SAS Institute, Cary, NC). The Fuwai Hospital institutional review board approved the study and waived the requirement for informed consent. The Fuwai Hospital has a data use agreement with the Agency for Healthcare Research and Quality to use the NIS data for this study.

**Results**

**Study Sample**

The final study sample included 380 hospitals, 77 in China and 303 in the United States. These hospitals included 51 408 patients, 32 040 (62.3%) from China and 19 368 (37.7%) from the United States. Compared with the US-CABG group, patients in China-CABG group were 3 years younger (mean [standard deviation], 61.3 [9.1] versus 64.6 [10.7]; P<0.001), less likely to be female (22.8% versus 25.8%; P<0.001), had higher cigarette use (52.7% versus 19.8%; P<0.001), and greater history of acute myocardial infarction or heart failure (34.8% versus 22.9%; P<0.001). However, the US-CABG group included more patients with common preexisting conditions, such as hyperlipidemia, atrial fibrillation, diabetes mellitus, hypertension, peripheral vascular disease, and renal failure (Table I). The mean (SD) annual hospital volumes were 416.1 (1694.4) and 317.8 (217.9) for hospitals in China and in the United States, respectively.

**In-Hospital Mortality**

There was no statistically significant difference in the observed all-age in-hospital mortalities between the China-CABG and US-CABG groups for the full study period (1.5% versus 1.5%; P=0.880) and the 2011 to 2013 period (1.2% versus 1.3%; P=0.458). In the 2007, 2008, and 2010 period, compared with the United States, China did not have significantly higher mortality for all-age patients (1.9% versus 1.6%; P=0.06) but did have significantly higher mortality for patients aged ≥65 years (3.1% versus 2.2%; P=0.005; Figure 1 and Table 2). However, this difference disappeared in the 2011 to 2013 period (1.23% versus 1.33%, P=0.47; 1.68% versus 1.65%, P=0.92; Table 2). The mixed model indicated that there was a relationship between country, and mortality changed over time for those aged ≥65 years. The mixed models also show that for patients aged ≥65 years, the odds of death were 1.43 (95% confidential interval, 1.12–1.82), 1.79 (95% confidential interval, 1.38–2.33), and 1.73 (95% confidential interval, 1.24–2.40) times higher for the China-CABG group than for the US-CABG group in the 2007 to 2008, 2010 period from the unadjusted, age- and sex-adjusted, and age-, sex-, and comorbidities-adjusted models, respectively (Figure 2, top). These differences were no longer significant in the 2011 to 2013 period (Figure 2, bottom). The odds of death for the China-CABG group in the 2011 to 2013 period were not significantly different from the those for US-CABG group for all-age, aged 18 to 64 years, and aged ≥65 years (Figure 2, bottom; Table II in the Data Supplement).

The propensity score analysis, which the model had an area under the receiver operating characteristic of 0.813 and 0.865 for 2007 to 2008, 2010 and 2011 to 2013 periods, respectively, were consistent with the above findings (Figure I in the Data Supplement). The simulation analysis showed that the difference in sampling approach between 2007 to 2011 and 2012 to 2013 periods for the US-CABG data did not influence the findings substantially (Figure II in the Data Supplement).

For patients aged 18 to 64 years, there was no statistically significant difference in the observed in-hospital postoperative 5-day mortalities between the China-CABG and US-CABG
groups in the 2007 to 2008, 2010 period (0.4% versus 0.7%; \( P = 0.063 \)) and the 2011 to 2013 period (0.4% versus 0.6%; \( P = 0.094 \)). For patients aged \( \geq 65 \) years, no statistically significant difference in 5-day mortality was found between the China-CABG and US-CABG groups in the 2007 to 2008, 2010 period (1.0% versus 1.2%; \( P = 0.357 \)). In the 2011 to 2013 period, compared with the United States, China had significantly lower mortality (0.7% versus 1.0%; \( P = 0.032 \)). This tendency persisted after adjustment for patient age, sex, and comorbidities (Figure 3).

**Table 1. Patient Characteristics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Overall (n=32040)</th>
<th>2007, 2008, and 2010 China (n=12078)</th>
<th>United States (n=10501)</th>
<th>2011–2013 China (n=19962)</th>
<th>United States (n=8867)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age, y, (SD)</td>
<td>61.3 (9.1)</td>
<td>64.6 (10.7)</td>
<td>61.6 (9.2)</td>
<td>64.4 (10.8)</td>
<td>61.1 (8.9)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>7296 (22.8)</td>
<td>4991 (26.0)</td>
<td>2632 (21.8)</td>
<td>2744 (26.1)</td>
<td>4664 (23.4)</td>
</tr>
<tr>
<td>Cardiovascular conditions and risk factors, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>18721 (58.4)</td>
<td>15185 (78.4)</td>
<td>7808 (64.7)</td>
<td>7973 (75.9)</td>
<td>10913 (54.7)</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>1010 (3.2)</td>
<td>2741 (14.2)</td>
<td>227 (1.9)</td>
<td>1362 (13.0)</td>
<td>783 (3.9)</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>387 (1.2)</td>
<td>284 (1.5)</td>
<td>93 (0.8)</td>
<td>144 (1.4)</td>
<td>294 (1.5)</td>
</tr>
<tr>
<td>Obesity</td>
<td>6624 (20.7)</td>
<td>3996 (20.6)</td>
<td>2248 (18.6)</td>
<td>1837 (17.5)</td>
<td>4376 (21.9)</td>
</tr>
<tr>
<td>Smoking</td>
<td>16896 (52.7)</td>
<td>3843 (19.8)</td>
<td>6100 (50.5)</td>
<td>1958 (18.9)</td>
<td>10796 (54.1)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>9479 (29.6)</td>
<td>8145 (42.1)</td>
<td>3770 (31.2)</td>
<td>4205 (40.0)</td>
<td>5709 (28.6)</td>
</tr>
<tr>
<td>Prior MI or HF</td>
<td>11139 (34.8)</td>
<td>4431 (22.9)</td>
<td>5078 (42.0)</td>
<td>2271 (21.6)</td>
<td>6061 (30.4)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>233 (0.7)</td>
<td>966 (5.0)</td>
<td>137 (1.1)</td>
<td>561 (5.3)</td>
<td>96 (0.5)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>13288 (41.5)</td>
<td>11525 (59.5)</td>
<td>6958 (57.6)</td>
<td>5547 (52.8)</td>
<td>6330 (31.7)</td>
</tr>
<tr>
<td>COPD</td>
<td>379 (1.2)</td>
<td>713 (3.7)</td>
<td>185 (1.5)</td>
<td>376 (3.6)</td>
<td>194 (1.0)</td>
</tr>
</tbody>
</table>

CABG indicates coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; HF, heart failure; MI, myocardial infarction; and SD, standard deviation.

**LOS and Major Discharge Disposition**

Overall, patients in China had significantly longer LOS than those in the United States. For preoperative, postoperative, and total hospital stay, respectively, the median (interquartile range) LOS across the entire study period between China-CABG and US-CABG groups were 9 (8) versus 1 (3), 9 (6) versus 6 (3), and 20 (12) versus 7 (5) days (all \( P < 0.001 \)). These differences did not change significantly between the 2007 to 2008, 2010 and 2011 to 2013 periods (Figure 4 and Table 2). When restricted to those patients who did not survive to...
discharge, Chinese patients also had significantly longer LOS than those in the United States. For preoperative, postoperative, and total hospital stay, respectively, the median (interquartile range) LOS among this subset of patients across the entire study period between the China-CABG and US-CABG groups were 10 (13) versus 1 (4), 8 (15) versus 5 (9), and 21 (22) versus 9 (4) days (all \( P<0.001 \)). Again, these differences did not change significantly between the 2007 to 2008, 2010 and 2011 to 2013 periods (Figure III in the Data Supplement). All living patients in the China-CABG group were discharged to home. In contrast, in the recent period for the US-CABG group, 43.8% of patients were discharged to home for self-care, and most received postacute services, including on-site home care (36.7%) or postacute care at nursing homes (13.0%).

### Discussion

In this study, we found similarities and differences among people undergoing CABG in the United States and Chinese large teaching and urban hospitals. There were some differences in patient profiles, with patients in China being younger and patients in the United States having more common preexisting conditions. Overall, China had statistically significantly higher mortality than the United States for patients aged \( \geq 65 \) years in 2007, 2008, and 2010, but this difference was not present in 2011 to 2013. In the 2011 to 2013 period, compared with the United States, China had significantly lower 5-day mortality after the CABG. We also found that CABG patients in China had significantly longer preoperative and postoperative LOS than patients in the United States.

Our findings are consistent with several potential explanations. First, the establishment of national database provides a comprehensive and scientifically rigorous approach for objective assessment of quality and performance measurement. The CCSR, which was similar to the Society for Thoracic Surgeons in the United States, was established in 2004 to advance CABG-related outcomes in China.\(^8\) The registry, which aims to evaluate surgical outcomes in patients undergoing cardiac surgery, has a committee comprising cardiac surgeons and researchers from universities and major teaching hospitals in China. In 2013, there were 734 hospitals in China offering cardiac surgery services, 209 of which have an annual volume of \( \geq 200 \) patients.\(^6\) Studies using CCSR data have shown that mortality and major complications among cardiac surgery in China have decreased over the period that the registry was instituted.\(^8,16\)

Second, China has made remarkable progress in improving population health over recent decades, including increasing healthcare insurance coverage to provide affordable basic healthcare services, improving infrastructure of hospitals and research facilities, strengthening the primary care system, financing public health, and reforming public hospitals.\(^17,19\) These national efforts may directly or indirectly improve health outcomes, including CABG mortality.

Third, quality of care and outcome measurements have become the key foci of recent healthcare improvements in China, with knowledge and standards being codified, shared, and used to guide practice.\(^20\) International healthcare conferences and further education overseas provide opportunities for Chinese surgeons to learn novel cardiovascular disease–related treatments, as well as outcome research topics from experts worldwide.\(^25\) Moreover, hospitals in China have much higher CABG volumes than hospitals in the United States. As a result Chinese surgeons may benefit more from the volume–outcome relationship in cardiac surgery than their peers in the United States.\(^22,23\) Such efforts and circumstances could have contributed to the recent improvement in CABG mortality in China.
Our study shows that there is room for improvement in CABG-specific length of hospital stay in Chinese hospitals. Currently, China has a CABG LOS that is an average of 13 days longer than that of the United States. Postacute care that aims to shorten LOS, including nursing homes, home health, rehabilitation, and long-term care, plays a key role in the entire episode of patient care in the United States.24–26 In contrast, there are many fewer nursing homes per capita in China compared with the United States. In 2013, only 4.3 million nursing home beds were available for nearly 125 million elderly, accommodating only 3.5% of China’s elderly population.27 It may be that expanding this capacity in China can shorten LOS and improve outcomes—but it could also increase costs and time away from home. There will be a need to study best approaches to optimize postacute care and reduce time in the hospital, which would shorten patient’s hospital stay and
Zheng et al  Outcomes of CABG Between China and United States

improve the current Chinese healthcare system. Moreover, implementation of fast-track protocols and clinical pathways may also help enable earlier extubation and mobilization of patients, streamline care, and reduce postoperative hospital stays in China. The outcomes of LOS might be affected by the effects of insurance coverage, including the insurance ownership, insurance type, and the reimbursement ratio. The insurance system in China is as complex as that in the United States, and it includes Medical Insurance for Urban Residents, Rural Cooperative Medical Systems, State-funded Public Medical System, and commercial health insurance. Considering the great variance in the health insurance type between China and the United States, we think more studies need to be conducted to gain deeper insights into the effects of insurance coverage on cardiac surgery outcomes in these 2 countries.

Another improvement needed is to reduce the difference in CABG care between large teaching hospitals and small, often nonteaching hospitals. Our findings were based on large teaching and urban hospitals that usually have more resources, but healthcare quality is advancing unevenly between urban and rural areas and among different regions in China. The majority of health providers are underqualified, especially in rural areas. Several measures have been taken to improve competencies for rural health professionals throughout the country, such as in-service training for Township Health Center health professionals, partnerships between urban hospitals and Township Health Centers, and job-transfer training for general practitioners. Furthermore, a new health management information system and performance-based management of health staff may enhance oversight.

Cardiothoracic surgical leadership in the United States challenged the surgical community to achieve an operative mortality rate of 1.0% for the performance of isolated CABG. A recent study indicates that achieving this goal would be feasible in only 60% of CABG patients, without making further improvements in processes of care. However, the possibility of achieving this aspiration in China remains unknown because of the increasing number of high-risk patients being referred for CABG.

Our study has several limitations. First, that the sources from which patient comorbidities were obtained differed between China and the United States. Such difference between clinically abstracted and administrative information is an ongoing challenge. To address this challenge, we also provided age- and sex-adjusted results that showed there was no substantial difference in mortality in recent years between China and the United States. Second, limited by the NIS data, we were not able to compare the in-hospital major complication rate, an important outcome for patients who underwent a CABG surgery, between China and the United States. Nevertheless, Safaie et al reported that based on a sample of 500 randomly selected patients aged ≥70 years who underwent a CABG surgery in the United States from 2004 to 2011, the post-CABG complication rates were 1.6%, 0.8%, 2.4%, 2.8%, and 2.4% for stroke, deep vein thrombosis, acute myocardial infarction, repeat surgery, and bleeding, respectively. By restricting our sample to the same period as the study of Safaie et al for all patients aged ≥70 years from the CCSR data, the complication rates were found to be 0.69% for stroke, 0.74% for acute myocardial infarction, 3.60% for reoperation for bleeding, 0.51% for reintubation, and 3.92% for renal failure. Third, restricted by our data source, we were not able to use a fixed period of follow-up for mortality, such as 30-day mortality. Finally, we only included ≥15% of all hospitals rendering services in the field of cardiac surgery in China in the study. Because these hospitals are all large and urban hospitals and they are the elite hospitals in China, our findings are not representative of China’s overall CABG care.

Conclusions

However, there was no statistically significant difference in the in-hospital CABG mortality during the period of 2011 to 2013 between Chinese and American large teaching and urban hospitals. But there is significant room for improvement in reducing CABG-related LOS in China. A better postacute care system for its hospitalized patients, especially for patients who have undergone an isolated CABG surgery, is warranted.
Outcomes of CABG Between China and United States

Acknowledgments

We thank the hospitals that participated in the CCSR for their contributions to this work. We also thank Anila Bakullari, senior business analyst at Qualidigm (http://www.qualidigm.org/), a leading health-care consulting and research company in the United States, and Paul Horak, BS, Postgraduate Associate in Medicine (Cardiology) at Yale University, for their valuable comments.

Sources of Funding

The study was funded by the National Key Research and Development Plan of China (2016YFC1002000), the Capital Health Development Scientific Research Projects (2016-1-031), and the Beijing Municipal Science and Technology Plan (D171100002917001).

Disclosures

Dr Krumholz is a recipient of research agreements from Medtronic and Johnson & Johnson (Janssen), through Yale, to develop methods of clinical trial data sharing; is the recipient of a grant from Medtronic for their valuable comments.

Advisory Board for Aetna; and is the founder of Hugo, a personal health information platform. The other authors report no conflicts.

References


Comparing Outcomes of Coronary Artery Bypass Grafting Among Large Teaching and Urban Hospitals in China and the United States
Zhe Zheng, Heng Zhang, Xin Yuan, Chenfei Rao, Yan Zhao, Yun Wang, Sharon-Lise Normand, Harlan M. Krumholz and Shengshou Hu

Circ Cardiovasc Qual Outcomes. 2017;10:
doi: 10.1161/CIRCOUTCOMES.116.003327
Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circoutcomes.ahajournals.org/content/10/6/e003327
Free via Open Access

Data Supplement (unedited) at:
http://circoutcomes.ahajournals.org/content/suppl/2017/06/13/CIRCOUTCOMES.116.003327.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/
Supplemental Material

Full title: Comparing Outcomes of Coronary Artery Bypass Grafting among Large Teaching and Urban Hospitals in China and United States

Contents

Ⅰ Supplemental Tables

eTable 1. ICD-9-CM codes to identify non-isolated CABG procedures, excluded from US-CABG cohort if 36.1x occurs with any of the following codes

eTable 2. Adjusted models

Ⅱ Supplemental Figures

eFigure 1. Frost plots of odds ratio of dying for patients in the China-CABG group versus patients in the US-CABG group based on the stabilized inverse probability weights' approach (propensity score approach)
CABG indicates coronary artery bypass grafting.

eFigure 2. Distributions of odds ratio of dying for patients in the China-CABG group versus patients in the US-CABG group based on simulation analysis (top panel: 2007-2008, 2010 period; bottom panel: 2011-2013 period)
CABG indicates coronary artery bypass grafting.

eFigure 3. Distributions of total, preoperative, and postoperative length of stays for patients underwent a coronary artery bypass grafting surgery and died at discharge by study period and by China and US
**Table 1. ICD-9-CM codes to identify non-isolated CABG procedures, excluded from US-CABG cohort if 36.1x occurs with any of the following codes:**

<table>
<thead>
<tr>
<th>ICD-9-CM code</th>
<th>Description</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.61</td>
<td>Percutaneous angioplasty or atherectomy of precerebral (extracranial) vessel(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>0.62</td>
<td>Percutaneous angioplasty or atherectomy of intracranial vessel(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>0.63</td>
<td>Percutaneous insertion of carotid artery stent(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>0.64</td>
<td>Percutaneous insertion of other precerebral (extracranial) artery stent(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>0.65</td>
<td>Percutaneous insertion of intracranial vascular stent(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>32.4x</td>
<td>Lobectomy with segmental resection of adjacent lobes of lung, excludes that with radical dissection [excision] of thoracic structures</td>
<td>Lobectomy</td>
</tr>
<tr>
<td>33.5x</td>
<td>Lung transplant</td>
<td>Lung Transplant</td>
</tr>
<tr>
<td>33.6</td>
<td>Combined heart-lung transplantation</td>
<td>Lung Transplant</td>
</tr>
<tr>
<td>35.00</td>
<td>Closed heart valvotomy, unspecified valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.01</td>
<td>Closed heart valvotomy, aortic valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.02</td>
<td>Closed heart valvotomy, mitral valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.03</td>
<td>Closed heart valvotomy, pulmonary valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.04</td>
<td>Closed heart valvotomy, tricuspid valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.10</td>
<td>Open heart valvuloplasty without replacement, unspecified valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.11</td>
<td>Open heart valvuloplasty of aortic valve without replacement</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.12</td>
<td>Open heart valvuloplasty of mitral valve without replacement</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.13</td>
<td>Open heart valvuloplasty of pulmonary valve without replacement</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.14</td>
<td>Open heart valvuloplasty of tricuspid valve without replacement</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.20</td>
<td>Replacement of unspecified heart valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.21</td>
<td>Replacement of aortic valve with tissue graft</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.22</td>
<td>Other replacement of aortic valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.23</td>
<td>Replacement of mitral valve with tissue graft</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.24</td>
<td>Other replacement of mitral valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.25</td>
<td>Replacement of pulmonary valve with tissue graft</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.26</td>
<td>Other replacement of pulmonary valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.27</td>
<td>Replacement of tricuspid valve with tissue graft</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.28</td>
<td>Other replacement of tricuspid valve</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.31</td>
<td>Operations on papillary muscle</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.32</td>
<td>Operations on chordae tendineae</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.33</td>
<td>Annuloplasty</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.34</td>
<td>Infundibulectomy</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.35</td>
<td>Operations on trabeculae carneae cordis</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.39</td>
<td>Operations on other structures adjacent to valves of heart</td>
<td>Valve procedures</td>
</tr>
<tr>
<td>35.41</td>
<td>Enlargement of existing atrial septal defect</td>
<td>Atrial Septal Defect</td>
</tr>
<tr>
<td>35.42</td>
<td>Creation of septal defect in heart</td>
<td>Atrial Septal Defect</td>
</tr>
<tr>
<td>35.50</td>
<td>Repair of unspecified septal defect of heart with prosthesis</td>
<td>Atrial Septal Defect</td>
</tr>
<tr>
<td>35.51</td>
<td>Repair of atrial septal defect with prosthesis, open</td>
<td>Atrial Septal Defect</td>
</tr>
</tbody>
</table>
technique

35.52 Repair of atrial septal defect with prosthesis, closed technique Atrial Septal Defect

35.53 Repair of ventricular septal defect with prosthesis, open technique Ventricular Septal Defect

35.54 Repair of endocardial cushion defect with prosthesis Ventricular Septal Defect

35.55 Repair of ventricular septal defect with prosthesis, closed technique Ventricular Septal Defect

35.60 Repair of unspecified septal defect of heart with tissue graft Ventricular Septal Defect

35.61 Repair of atrial septal defect with tissue graft Atrial Septal Defect

35.62 Repair of ventricular septal defect with tissue graft Ventricular Septal Defect

35.63 Repair of endocardial cushion defect with tissue graft Ventricular Septal Defect

35.70 Other and unspecified repair of unspecified septal defect of heart Ventricular Septal Defect

35.71 Other and unspecified repair of atrial septal defect Atrial Septal Defect

35.72 Other and unspecified repair of ventricular septal defect Ventricular Septal Defect

35.73 Other and unspecified repair of endocardial cushion defect Ventricular Septal Defect

35.81 Total repair of tetralogy of Fallot Correction of congenital anomalies

35.82 Total repair of total anomalous pulmonary venous connection Correction of congenital anomalies

35.83 Total repair of truncus arteriosus Correction of congenital anomalies

35.84 Total correction of transposition of great vessels, not elsewhere classified Correction of congenital anomalies

35.91 Interatrial transposition of venous return Correction of congenital anomalies

35.92 Creation of conduit between right ventricle and pulmonary artery Correction of congenital anomalies

35.93 Creation of conduit between left ventricle and aorta Correction of congenital anomalies

35.94 Creation of conduit between atrium and pulmonary artery Correction of congenital anomalies

35.95 Revision of corrective procedure on heart Correction of congenital anomalies

35.96 Percutaneous valvuloplasty Valve procedures

35.98 Other operations on septa of heart Ventricular Septal Defect

35.99 Other operations on valves of heart Other valve procedures

37.31 Pericardiectomy Repair/restoration of pericardium

37.32 Excision of aneurysm of heart Other open cardiac procedures

37.33 Excision or destruction of other lesion or tissue of heart, open approach Other open cardiac procedures

37.35 Partial ventriculectomy Other open cardiac procedures

37.51 Heart transplantation Heart transplant

37.52 Implantation of total internal biventricular heart replacement system Heart replacement procedures

37.53 Replacement or repair of thoracic unit of (total) replacement heart system Heart replacement procedures

37.54 Replacement or repair of other implantable component of (total) replacement heart system Heart replacement procedures
37.55 Removal of internal biventricular heart replacement system
Heart replacement procedures

37.63 Repair of heart assist system
Circulatory assist devices (includes VAD)

37.67 Implantation of cardiomyostimulation system
Circulatory assist devices (includes VAD)

38.11 Head and Neck Endarterectomy
Head, neck, intracranial vascular procedure

38.12 Endarterectomy, other vessels of head and neck
Head, neck, intracranial vascular procedure

38.14 Endarterectomy of Aorta
Aorta or other non-cardiac arterial bypass procedures

38.15 Thoracic Endarterectomy
Aorta or other non-cardiac arterial bypass procedures

38.16 Endarterectomy: Excision of tunica intima of artery to relieve arterial walls thickened by plaque or chronic inflammation. Location includes abdominal arteries excluding abdominal aorta: Celiac, Gastric, Hepatic, Iliac, Mesenteric, Renal, Splenic, Umbi
Aorta or other non-cardiac arterial bypass procedures

Aorta or other non-cardiac arterial bypass procedures

38.34 Resection of vessel with replacement: Angiectomy, excision of aneurysm (arteriovenous), blood vessel (lesion) with anastomosis (4=aorta, abdominal)
Aorta or other non-cardiac arterial bypass procedures

38.42 Resection of vessel with replacement: Angiectomy, excision of aneurysm with replacement (2= other vessels of head and neck; carotid, jugular)
Head, neck, intracranial vascular procedure

38.44 Resection of vessel with replacement, aorta, abdominal
Aorta or other non-cardiac arterial bypass procedures

38.45 Resection of vessel with replacement, thoracic vessels
Aorta or other non-cardiac arterial bypass procedures

39.21 Caval-pulmonary artery anastomosis
Aorta or other non-cardiac arterial bypass procedures

39.22 Aorta-subclavian-carotid bypass
Aorta or other non-cardiac arterial bypass procedures

39.23 Other intrathoracic vascular shunt or bypass
Aorta or other non-cardiac arterial bypass procedures

39.24 Aorta-renal bypass
Aorta or other non-cardiac arterial bypass procedures

39.25 Aorta-iliac-femoral bypass
Aorta or other non-cardiac arterial bypass procedures

39.26 Other intra-abdominal vascular shunt or bypass
Aorta or other non-cardiac arterial bypass procedures

39.28 Extracranial-intracranial (EC-IC) vascular bypass
Head, neck, intracranial vascular procedure

39.29 Other (peripheral) vascular shunt or bypass
Aorta or other non-cardiac arterial bypass procedures

39.71 Endovascular implantation of graft in abdominal aorta
Aorta or other non-cardiac arterial bypass procedures

39.72 Endovascular embolization or occlusion of head and neck vessels
Head, neck, intracranial vascular procedure

39.73 Endovascular implantation of graft in thoracic aorta
Aorta or other non-cardiac arterial bypass procedures
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>39.74</td>
<td>Endovascular removal of obstruction from head and neck vessel(s)</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>39.75</td>
<td>Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>39.76</td>
<td>Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils</td>
<td>Head, neck, intracranial vascular procedure</td>
</tr>
<tr>
<td>39.79</td>
<td>Other endovascular procedures on other vessels</td>
<td>Aorta or other non-cardiac arterial bypass procedures</td>
</tr>
<tr>
<td>85.22</td>
<td>Resection of quadrant of breast</td>
<td>Mastectomy</td>
</tr>
<tr>
<td>85.23</td>
<td>Subtotal Mastectomy, which excludes quadrant resection (85.22)</td>
<td>Mastectomy</td>
</tr>
<tr>
<td>85.4x</td>
<td>Mastectomy - includes simple/extended simple, unilateral/bilateral, radical/extended radical</td>
<td>Mastectomy</td>
</tr>
</tbody>
</table>

**Reference**

## eTable 2. Adjusted models

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>China: aged 18-64</td>
<td>1.17 (0.81-1.68)</td>
<td>0.3995</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>China: aged 65+</td>
<td>1.43 (1.12-1.82)</td>
<td>0.0041</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>China: all age</td>
<td>1.21 (0.99-1.48)</td>
<td>0.0589</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>US (Ref.)</td>
<td>1.00 (1.00-1.00)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age-sex adjusted</td>
<td>China: aged 18-64</td>
<td>1.19 (0.83-1.71)</td>
<td>0.3452</td>
</tr>
<tr>
<td>Age-sex adjusted</td>
<td>China: aged 65+</td>
<td>1.79 (1.38-2.33)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age-sex adjusted</td>
<td>China: all age</td>
<td>1.52 (1.24-1.88)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age-sex adjusted</td>
<td>US (Ref.)</td>
<td>1.00 (1.00-1.00)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age-sex-comorbidity adjusted</td>
<td>China: aged 18-64</td>
<td>1.36 (0.88-2.11)</td>
<td>0.1719</td>
</tr>
<tr>
<td>Age-sex-comorbidity adjusted</td>
<td>China: aged 65+</td>
<td>1.73 (1.24-2.40)</td>
<td>0.0011</td>
</tr>
<tr>
<td>Age-sex-comorbidity adjusted</td>
<td>China: all age</td>
<td>1.58 (1.22-2.04)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Age-sex-comorbidity adjusted</td>
<td>US (Ref.)</td>
<td>1.00 (1.00-1.00)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>
**eFigure 1.** Frost plots of odds ratio of dying for patients in the China-CABG group versus patients in the US-CABG group based on the stabilized inverse probability weights' approach (propensity score approach)
**eFigure 2.** Distributions of odds ratio of dying for patients in the China-CABG group versus patients in the US-CABG group based on simulation analysis (top panel: 2007-2008, 2010 period; bottom panel: 2011-2013 period)
eFigure 3. Distributions of total, preoperative, and postoperative length of stays for patients underwent a coronary artery bypass grafting surgery and died at discharge by study period and by China and US.